Moreover, serum levels of the ImpL2 homolog in humans, the insulin growth factor binding protein 7 (IGFBP7), have been shown to be positively correlated with insulin resistance, body mass index and the risk of metabolic syndrome47,48, while the treatment of mouse and human hepatocytes with IGFBP7 increased LDL and VLDL production49. This evidence concerns the gene IGFBP7 and Insulin resistance.